• Molecular NameNaratriptan
  • Synonymnaratriptan
  • Weight335.472
  • Drugbank_IDDB00952
  • ACS_NO121679-13-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.13
  • pkaN/A
  • LogD (pH=7, predicted)-0.35
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.75
  • LogSw (predicted, AB/LogsW2.0)0.35
  • Sw (mg/ml) (predicted, ACD/Labs)0.24
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds5
  • TPSA73.58
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches.
  • Absorption_value70.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability69.0
  • Protein binding29.5
  • Volume of distribution (VD)170 L
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPrimarily hepatic. In vitro, naratriptan is metabolized by a wide range of cytochrome P450 isoenzymes into a number of inactive metabolites.
  • Half life4.5~5.5 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A